
SGLT2i Reduces Hospitalizations, Mortality in Patients With Heart Failure
The Heart Failure Society of America 2024 Annual Meeting featured presentations exploring the benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for patients with heart failure.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a pivotal class of medications in the treatment of
A collection of abstracts presented at the Heart Failure Society of America 2024 Annual Meeting delved into these challenges and explored the benefits of SGLT2i in the patient population.
READ MORE:
Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our
References
1. Chen B, Miller M, Chen D, et al. Increasing the utilization of SGLT2i prescriptions at discharge for heart failure patients: A resident-led quality-improvement initiative. Presented at: Heart Failure Society of America 2024 Annual Meeting; September 27-30, 2024; Atlanta, GA. Poster 1306-116.
2. Mir J. Sodium glucose cotransporter 2 inhibitors in heart failure: meta-analysis. Presented at: Heart Failure Society of America 2024 Annual Meeting; September 27-30, 2024; Atlanta, GA. Poster 1204-295.
3. Addo B. Dapagliflozin in heart failure: a comprehensive meta-analysis on functional capacity, symptoms, and safety outcomes. Presented at: Heart Failure Society of America 2024 Annual Meeting; September 27-30, 2024; Atlanta, GA. Poster 1244-039.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.


























































































































































